Grindeks

AS Grindex
Grindex
IndustryPharmaceuticals
Founded1946
Headquarters53 Krustpils St,
Riga
,
Latvia
Key people
Kirovs Lipmans(Chairman of the Council), Juris Hmelnickis (CEO), Janis Romanovskis (Chief Finance and Administrative Officer), Andrejs Liberts, (Commercial director)
ProductsMildronate; Ftorafur
Production output
Pharmaceuticals
Revenue187 million EUR (2020)
29,142,630 (2022) Edit this on Wikidata
Total assets198,324,446 Euro (2022) Edit this on Wikidata
OwnerLiplat Holding, Ltd.
Number of employees
1498 (2021)
SubsidiariesJSC Kalceks, JSC Tallinn Pharmaceutical Plant, HBM Pharma Ltd.
Websitewww.grindeks.eu

JSC Grindex (branded as Grindex), or simply Grindeks, is an internationally operating Latvian pharmaceutical company with headquarters in Riga, Latvia. Its portfolio consists of original products, generics, and active pharmaceutical ingredients. It mostly focuses on cardiovascular, central nervous system, anti-cancer, and diabetes medicines. Grindex is the leading pharmaceutical manufacturer in the Baltic States. In 2021, Grindex imported products to more than 90 countries.

Grindex Group consists of JSC Grindex and its four subsidiaries — JSC Kalceks (Latvia), HBM Pharma Ltd. (Slovakia), JSC Tallinn Pharmaceutical Plant (Estonia) and Namu apsaimniekošanas projekti Ltd. (Latvia).


From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Tubidy